AustralieFrV1, Main, Merge, bibRecord, 005F97

Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure: Results From the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) Study

Identifieur interne : 005F97 ( Main/Merge ); précédent : 005F96; suivant : 005F98

Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure: Results From the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) Study

Auteurs : Karl Swedberg [Suède] ; Faiez Zannad [France] ; John J. V. Mcmurray [Royaume-Uni] ; Henry Krum [Australie] ; Dirk J. Van Veldhuisen [Pays-Bas] ; Harry Shi [États-Unis] ; John Vincent [États-Unis] ; Bertram Pitt [États-Unis]

Source :

Journal of the American College of Cardiology [ 0735-1097 ] ; 2012.

RBID : Pascal:12-0208807

Descripteurs français

Pascal (Inist)
- Fibrillation auriculaire, Insuffisance cardiaque, Eplérénone, Résultat, Homme, Malade, Hospitalisation, Survie, Pronostic, Appareil circulatoire, Cardiologie.
Wicri :
- topic : Homme, Hospitalisation.

English descriptors

KwdEn :
- Atrial fibrillation, Cardiology, Circulatory system, Eplerenone, Heart failure, Hospitalization, Human, Patient, Prognosis, Result, Survival.

Abstract

Objectives The purpose of this study was to analyze the incidence of new atrial fibrillation or flutter (AFF) in the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure) database. Background Aldosterone antagonism in heart failure might influence atrial fibrosis and remodeling and, therefore, risk of developing AFF. The development of new AFF was a pre-specified secondary endpoint in the EMPHASIS-HF study. Methods Patients in New York Heart Association functional class II and with ejection fraction ≤35% were eligible for EMPHASIS-HF. History of AFF at baseline was reported by investigators using the study case report form. New onset AFF (in those with no history of AFF at baseline) was reported using a specific endpoint form; in a sensitivity analysis we also examined the effect of eplerenone on AFF reported as an adverse event. Results New onset AFF was significantly reduced by eplerenone: 25 of 911 (2.7%) versus 40 of 883 (4.5%) in the placebo group (hazard ratio [HR]: 0.58, 95% confidence interval [CI]: 0.35 to 0.96; p = 0.034). The reduction in the primary endpoint with eplerenone was similar among patients with and without AFF at baseline (HR: 0.60, 95% CI: 0.46 to 0.79 vs. HR: 0.70, 95% CI: 0.57 to 0.85, respectively; p for interaction = 0.41). The risk of cardiovascular (CV) death or hospital admission for worsening heart failure, the primary endpoint, was not significantly different in subjects with and without AFF at baseline (both study groups combined: HR: 1.23, 95% CI: 0.81 to 1.86; p = 0.33). Conclusions In patients with systolic heart failure and mild symptoms, eplerenone reduced the incidence of new onset AFF. The effects of eplerenone on the reduction of major CV events were similar in patients with and without AFF at baseline.

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 001394
to stream PascalFrancis, to step Curation: 004B19
to stream PascalFrancis, to step Checkpoint: 001162

Links to Exploration step

Pascal:12-0208807

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure: Results From the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) Study</title>
<author><name sortKey="Swedberg, Karl" sort="Swedberg, Karl" uniqKey="Swedberg K" first="Karl" last="Swedberg">Karl Swedberg</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg</s1>
<s2>Göteborg</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<wicri:noRegion>Göteborg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Inserm, Centre d'Investigation Clinique CIC 9501 and U961, CHU and Department of Cardiology, University of Nancy</s1>
<s2>Nancy</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Grand Est</region>
<region type="old region">Lorraine (région)</region>
<settlement type="city">Nancy</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcmurray, John J V" sort="Mcmurray, John J V" uniqKey="Mcmurray J" first="John J. V." last="Mcmurray">John J. V. Mcmurray</name>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>The British Heart Foundation Cardiovascular Research Centre, University of Glasgow</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Glasgow</settlement>
<region type="country">Écosse</region>
</placeName>
<orgName type="university">Université de Glasgow</orgName>
</affiliation>
</author>
<author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Epidemiology and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics, Monash University</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Veldhuisen, Dirk J Van" sort="Veldhuisen, Dirk J Van" uniqKey="Veldhuisen D" first="Dirk J. Van" last="Veldhuisen">Dirk J. Van Veldhuisen</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Department of Cardiology, Thorax Centre, University Medical Centre</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
<placeName><settlement type="city">Groningue</settlement>
<region nuts="2" type="province">Groningue (province)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shi, Harry" sort="Shi, Harry" uniqKey="Shi H" first="Harry" last="Shi">Harry Shi</name>
<affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Pfizer Inc.</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vincent, John" sort="Vincent, John" uniqKey="Vincent J" first="John" last="Vincent">John Vincent</name>
<affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Pfizer Inc.</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pitt, Bertram" sort="Pitt, Bertram" uniqKey="Pitt B" first="Bertram" last="Pitt">Bertram Pitt</name>
<affiliation wicri:level="2"><inist:fA14 i1="07"><s1>University of Michigan School of Medicine</s1>
<s2>Ann Arbor, Michigan</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0208807</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0208807 INIST</idno>
<idno type="RBID">Pascal:12-0208807</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001394</idno>
<idno type="wicri:Area/PascalFrancis/Curation">004B19</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001162</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001162</idno>
<idno type="wicri:doubleKey">0735-1097:2012:Swedberg K:eplerenone:and:atrial</idno>
<idno type="wicri:Area/Main/Merge">005F97</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure: Results From the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) Study</title>
<author><name sortKey="Swedberg, Karl" sort="Swedberg, Karl" uniqKey="Swedberg K" first="Karl" last="Swedberg">Karl Swedberg</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg</s1>
<s2>Göteborg</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<wicri:noRegion>Göteborg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Inserm, Centre d'Investigation Clinique CIC 9501 and U961, CHU and Department of Cardiology, University of Nancy</s1>
<s2>Nancy</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Grand Est</region>
<region type="old region">Lorraine (région)</region>
<settlement type="city">Nancy</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcmurray, John J V" sort="Mcmurray, John J V" uniqKey="Mcmurray J" first="John J. V." last="Mcmurray">John J. V. Mcmurray</name>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>The British Heart Foundation Cardiovascular Research Centre, University of Glasgow</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Glasgow</settlement>
<region type="country">Écosse</region>
</placeName>
<orgName type="university">Université de Glasgow</orgName>
</affiliation>
</author>
<author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Epidemiology and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics, Monash University</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Veldhuisen, Dirk J Van" sort="Veldhuisen, Dirk J Van" uniqKey="Veldhuisen D" first="Dirk J. Van" last="Veldhuisen">Dirk J. Van Veldhuisen</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Department of Cardiology, Thorax Centre, University Medical Centre</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
<placeName><settlement type="city">Groningue</settlement>
<region nuts="2" type="province">Groningue (province)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shi, Harry" sort="Shi, Harry" uniqKey="Shi H" first="Harry" last="Shi">Harry Shi</name>
<affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Pfizer Inc.</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vincent, John" sort="Vincent, John" uniqKey="Vincent J" first="John" last="Vincent">John Vincent</name>
<affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Pfizer Inc.</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pitt, Bertram" sort="Pitt, Bertram" uniqKey="Pitt B" first="Bertram" last="Pitt">Bertram Pitt</name>
<affiliation wicri:level="2"><inist:fA14 i1="07"><s1>University of Michigan School of Medicine</s1>
<s2>Ann Arbor, Michigan</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of the American College of Cardiology</title>
<title level="j" type="abbreviated">J. Am. Coll. Cardiol.</title>
<idno type="ISSN">0735-1097</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of the American College of Cardiology</title>
<title level="j" type="abbreviated">J. Am. Coll. Cardiol.</title>
<idno type="ISSN">0735-1097</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Atrial fibrillation</term>
<term>Cardiology</term>
<term>Circulatory system</term>
<term>Eplerenone</term>
<term>Heart failure</term>
<term>Hospitalization</term>
<term>Human</term>
<term>Patient</term>
<term>Prognosis</term>
<term>Result</term>
<term>Survival</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Fibrillation auriculaire</term>
<term>Insuffisance cardiaque</term>
<term>Eplérénone</term>
<term>Résultat</term>
<term>Homme</term>
<term>Malade</term>
<term>Hospitalisation</term>
<term>Survie</term>
<term>Pronostic</term>
<term>Appareil circulatoire</term>
<term>Cardiologie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
<term>Hospitalisation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objectives The purpose of this study was to analyze the incidence of new atrial fibrillation or flutter (AFF) in the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure) database. Background Aldosterone antagonism in heart failure might influence atrial fibrosis and remodeling and, therefore, risk of developing AFF. The development of new AFF was a pre-specified secondary endpoint in the EMPHASIS-HF study. Methods Patients in New York Heart Association functional class II and with ejection fraction ≤35% were eligible for EMPHASIS-HF. History of AFF at baseline was reported by investigators using the study case report form. New onset AFF (in those with no history of AFF at baseline) was reported using a specific endpoint form; in a sensitivity analysis we also examined the effect of eplerenone on AFF reported as an adverse event. Results New onset AFF was significantly reduced by eplerenone: 25 of 911 (2.7%) versus 40 of 883 (4.5%) in the placebo group (hazard ratio [HR]: 0.58, 95% confidence interval [CI]: 0.35 to 0.96; p = 0.034). The reduction in the primary endpoint with eplerenone was similar among patients with and without AFF at baseline (HR: 0.60, 95% CI: 0.46 to 0.79 vs. HR: 0.70, 95% CI: 0.57 to 0.85, respectively; p for interaction = 0.41). The risk of cardiovascular (CV) death or hospital admission for worsening heart failure, the primary endpoint, was not significantly different in subjects with and without AFF at baseline (both study groups combined: HR: 1.23, 95% CI: 0.81 to 1.86; p = 0.33). Conclusions In patients with systolic heart failure and mild symptoms, eplerenone reduced the incidence of new onset AFF. The effects of eplerenone on the reduction of major CV events were similar in patients with and without AFF at baseline.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>France</li>
<li>Pays-Bas</li>
<li>Royaume-Uni</li>
<li>Suède</li>
<li>États-Unis</li>
</country>
<region><li>Grand Est</li>
<li>Groningue (province)</li>
<li>Lorraine (région)</li>
<li>Michigan</li>
<li>Victoria (État)</li>
<li>Écosse</li>
<li>État de New York</li>
</region>
<settlement><li>Glasgow</li>
<li>Groningue</li>
<li>Melbourne</li>
<li>Nancy</li>
</settlement>
<orgName><li>Université de Glasgow</li>
</orgName>
</list>
<tree><country name="Suède"><noRegion><name sortKey="Swedberg, Karl" sort="Swedberg, Karl" uniqKey="Swedberg K" first="Karl" last="Swedberg">Karl Swedberg</name>
</noRegion>
</country>
<country name="France"><region name="Grand Est"><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name>
</region>
</country>
<country name="Royaume-Uni"><region name="Écosse"><name sortKey="Mcmurray, John J V" sort="Mcmurray, John J V" uniqKey="Mcmurray J" first="John J. V." last="Mcmurray">John J. V. Mcmurray</name>
</region>
</country>
<country name="Australie"><region name="Victoria (État)"><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name>
</region>
</country>
<country name="Pays-Bas"><region name="Groningue (province)"><name sortKey="Veldhuisen, Dirk J Van" sort="Veldhuisen, Dirk J Van" uniqKey="Veldhuisen D" first="Dirk J. Van" last="Veldhuisen">Dirk J. Van Veldhuisen</name>
</region>
</country>
<country name="États-Unis"><region name="État de New York"><name sortKey="Shi, Harry" sort="Shi, Harry" uniqKey="Shi H" first="Harry" last="Shi">Harry Shi</name>
</region>
<name sortKey="Pitt, Bertram" sort="Pitt, Bertram" uniqKey="Pitt B" first="Bertram" last="Pitt">Bertram Pitt</name>
<name sortKey="Vincent, John" sort="Vincent, John" uniqKey="Vincent J" first="John" last="Vincent">John Vincent</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005F97 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 005F97 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     Pascal:12-0208807
   |texte=   Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure: Results From the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) Study
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure: Results From the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) Study

Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure: Results From the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) Study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri